Research programme: cancer therapeutics - Heidelberg

Drug Profile

Research programme: cancer therapeutics - Heidelberg

Alternative Names: HDP 15.0001; HDP 150001

Latest Information Update: 16 Nov 2010

Price : $50

At a glance

  • Originator Heidelberg Pharma
  • Class Purine nucleosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 16 May 2005 Preclinical trials in Non-Hodgkin's lymphoma in Germany (unspecified route)
  • 16 May 2005 Preclinical trials in Solid tumours in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top